Skip to main content
TipRanks
Go Ultimate75% OFF

Personalis (04X) Q1 2026 Earnings Report

2 Followers

DE:04X Q1 2026 EPS Results

Actual EPS
-EUR 0.26
Consensus EPS
-EUR 0.24
Beat/Miss
Missed by -EUR 0.02
One Year Ago EPS
-EUR 0.16

DE:04X Q1 2026 Revenue Results

Actual Revenue
EUR 13.85M
Expected Revenue
EUR 12.97M
Beat/Miss
Beat by +EUR 883.71K
YoY Revenue Growth
-24.91%

Earnings Announcement Details

Quarter
Q1 2026
Date
05/07/2026
Time
After Close
Conference Call
Thursday, May 7, 2026
DE:04X Upcoming Earnings

Personalis's next earnings date is estimated for February 25, 2027, based on past reporting schedules.

Q1 2026 Earnings Call Audio

DE:04X Q1 2026 Earnings Call
0:00 / 0:00

Q1 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q1 2026 Earnings Call Summary

Q1 2026
Earnings Call Date:May 07, 2026|% Change Since:159.20%|
Earnings Call Sentiment|Neutral

The call balanced strong operational and clinical momentum (rapid test volume growth, compelling real-world and study data, growing MRD pipeline, reimbursement wins and a healthy cash balance) against material near-term financial headwinds (severe gross margin compression, higher operating expenses, widening net loss and elevated cash burn). Management frames the negative margin and revenue mix trends as intentional investments to capture MRD market share and expects margins and ASPs to improve as reimbursed volume scales, but the timing of reimbursement and conversion to higher-margin revenue remains a key risk.

Company Guidance

Personalis reaffirmed full‑year 2026 revenue guidance of $78–$80 million, expecting clinical revenue of $10–$11M (breast and lung surveillance), pharma/tests and other customers of $55–$56M, population sequencing/enterprise ~ $13M, strategic revenue to more than double to $30–$32M and biopharma MRD revenue of $20–$21M, and it projects 43,000–45,000 clinical tests for 2026. Management expects full‑year gross margin of 15%–20% (Q1 was 1.8% with >2,000 bps dilution from unreimbursed tests and the first half as the trough), a net loss of ~ $105M, and cash usage of ~ $100M; Q1 results cited $15.5M revenue, >7,800 clinical tests (+26% sequential, +258% YoY), $4.5M strategic revenue, $3.1M MRD revenue, $1.4M clinical revenue, operating expenses of $32.4M (R&D $14.5M; SG&A $17.9M), net loss $30.0M, and $233.2M cash and short‑term investments after ~$28M cash used (including ~$5M one‑time incentive).

  • Rapid clinical volume accelerationDelivered >7,800 clinical tests in Q1 2026, a 26% sequential increase vs Q4 and a 258% year-over-year increase, with a 2026 annual volume target of 43,000 to 45,000 tests.
  • Strong clinical adoption and retentionSurpassed 1,000 ordering physicians in the quarter and reported physician retention above 98% over recent quarters, indicating deepening usage and customer stickiness.
  • Compelling clinical and real-world dataKey evidence highlights: NeoPrism CRC collaborators reported 100% negative predictive value for relapse in a colorectal cohort; real-world testing of 10,000 patients showed ~40% of positive detections in the ultrasensitive range (<100 ppm) across 14 cancer types; DARWIN II data showed early ctDNA clearance linked to a ~5x higher likelihood of 3-year progression-free status.
  • Product and roadmap progressLaunched a pilot of the real-time Variant Tracker to monitor tumor biology changes during therapy, expanding clinical utility beyond presence/absence MRD detection.
  • Growing MRD biopharma opportunityQ1 biopharma MRD revenue was $3.1M with a full-year MRD revenue target of $20M–$21M; strategic revenue (clinical + biopharma MRD adoption) was $4.5M in Q1 with guidance to more than double strategic revenue to $30M–$32M for 2026.
  • Reimbursement progress and clinical revenue rampMedicare coverage wins for breast (Nov 2025) and lung (Feb 2026) surveillance are live; clinical revenue grew to $1.4M in Q1 from $0.3M in Q1 2025 (~+367%), supporting higher ASPs and future margin expansion as reimbursed volume scales.
  • Strong liquidity and runwayEnded Q1 with $233.2M in cash and short-term investments, no material debt, and used ~$28M of cash in Q1 (including a ~$5M one-time incentive payment), supporting planned investments to scale MRD strategy.

DE:04X Earnings History

DE:04X earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 25, 20272026 (Q4)-0.21--0.23――
Nov 04, 20262026 (Q3)-0.24-0.29-0.21-33.33% (-0.07)
Aug 04, 20262026 (Q2)-0.24-0.27-0.21-30.43% (-0.06)
May 07, 20262026 (Q1)-0.24-0.26-0.16-61.11% (-0.10)
Feb 26, 20262025 (Q4)-0.26-0.23-0.21-13.04% (-0.03)
Nov 04, 20252025 (Q3)-0.24-0.21-0.5762.50% (+0.36)
Aug 05, 20252025 (Q2)-0.21-0.21-0.214.17% (+0.01)
May 06, 20252025 (Q1)-0.22-0.16-0.2330.77% (+0.07)
Feb 27, 20252024 (Q4)-0.25-0.21-0.4857.41% (+0.28)
Nov 06, 20242024 (Q3)-0.31-0.57-0.54-6.67% (-0.04)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed